scholarly journals Comparison between hyaluronic acid filler and botulinum toxin type A in the treatment of thyroid upper eyelid retraction

2020 ◽  
Vol 12 ◽  
pp. 251584142097911
Author(s):  
Mahaa Hassan Hussien ◽  
Elham Abd El-Wahed Hassan ◽  
Nermien Salah El-Dien Mohammed El-Haddad
Keyword(s):  
Hyaluronic Acid ◽  
Botulinum Toxin ◽  
Botulinum Toxin Type A ◽  
Type A ◽  
Botulinum Toxin Type ◽  
Eyelid Retraction ◽  
Upper Eyelid ◽  
Significant Difference ◽  
Upper Eyelid Retraction ◽  
The Difference

Purpose: The aim of this study was to compare between hyaluronic acid filler (HA) and botulinum toxin type A (BTX-A) in the treatment of thyroid upper eyelid retraction. Study design: This was a prospective comparative study. Methods: A total of 50 eyes with upper thyroid eyelid retraction were divided into 2 groups. Each group included 25 eyes, (a) hyaluronic acid filler (HA) group: received subconjunctival HA injection and (b) botulinum toxin (BTX-A) group: received subconjunctival botulinum toxin type A injection. Full ophthalmic examination and thyroid profile were done. Marginal reflex distance 1 (MRD1) and total palpebral fissure height (TPFH) were measured before and after injection weekly for 6 months. Results: There is no significant difference between the two groups regarding MRD1 till the 10th week of follow up, then it became significant from the 11th to 15th week with better results in HA filler group, then the difference between the two groups become highly significant from the 16th week afterward with better results for the HA filler over the BTX-A. With regard to TPFH, there were significant differences between the BTX-A group and the HA group with a better result in BTX-A group in the first 8 weeks. Then the difference became insignificant till the 18th week. Then the difference became significant from the 19th till the 24th week with a better result in HA group. Conclusion: HA filler has better result in treating thyroid upper eyelid retraction than BTX-A due to its predictable controllable effect, also, due to the longer duration of action and fewer side effects.

Botulinum Toxin Type A for Dysthyroid Upper Eyelid Retraction

2004 ◽  
Vol 20 (3) ◽  
pp. 181-185 ◽  
Author(s):  
K. E. Morgenstern ◽  
J. Evanchan ◽  
J. A. Foster ◽  
K. V. Cahill ◽  
J. A. Burns ◽  
...  
Keyword(s):  
Botulinum Toxin ◽  
Botulinum Toxin Type A ◽  
Type A ◽  
Botulinum Toxin Type ◽  
Eyelid Retraction ◽  
Upper Eyelid ◽  
Upper Eyelid Retraction

Response re: ???Botulinum Toxin Type A for Dysthyroid Upper Eyelid Retraction???

2005 ◽  
Vol 21 (1) ◽  
pp. 81-82
Author(s):  
K E. Morgenstern ◽  
K V. Cahill ◽  
J A. Foster ◽  
J A. Burns ◽  
D E. E. Holck ◽  
...  
Keyword(s):  
Botulinum Toxin ◽  
Botulinum Toxin Type A ◽  
Type A ◽  
Botulinum Toxin Type ◽  
Eyelid Retraction ◽  
Upper Eyelid ◽  
Upper Eyelid Retraction

scholarly journals Botulinum toxin type a for the treatment of spasticity in children with cerebral palsy

2007 ◽  
Vol 64 (8) ◽  
pp. 513-518 ◽  
Author(s):  
Lidija Dimitrijevic ◽  
Ivona Stankovic ◽  
Vesna Zivkovic ◽  
Aleksandra Mikov ◽  
Hristina Colovic ◽  
...  
Keyword(s):  
Botulinum Toxin ◽  
Range Of Motion ◽  
Botulinum Toxin Type A ◽  
Type A ◽  
Botulinum Toxin Type ◽  
Group I ◽  
Active Range Of Motion ◽  
Significant Difference ◽  
Motor Outcome ◽  
Group Ii

Background/Aim. Cerebral palsy (CP) is the most common physical disability in childhood. Children have problems with motor functions as a result of limbs spasticity, which leads to severe contractures and limbs deformity. There is a growing interest in the therapeutic role of botulinum toxin type A (BTA) in CP. The aim of this study was to examine the effects of BTA on spasticity, active range of motion and functional motor outcomes in children with CP. Methods. This study included 42 children of both sexes, aged 2?6 years, with spastic CP, divided into two groups: group I (21 child) treated with BTA and physical therapy, and group II (21 child) treated with physical therapy only. The following parameters were analyzed: spasticity; active range of motion of the hip, knee and ankle, and functional motor outcome. These parameters measurements were carried out four times in both groups: before the treatment, three, eight and 16 weeks after the beginning of the treatment. The obtained results were statistically processed and compared. Results. There was no evidence of any significant difference between the groups before the treatment. After eight weeks there was a remarkable difference concerning spasticity reducing on behalf of the group I (group I - 0.76?0.51 vs. II group - 2.17?0.64; p < 0.0001). There was statistically significant difference concerning active range of motion increasing on behalf of the group I (hip abduction: group I - 44.37?1.130 vs. group II - 32.61?8,070, p < 0,01; knee extension: group I - 0,77?1.820 vs. II group - 14.99?7.610, p < 0.01; dorsiflexion of the foot: group I - 11.50?6.080 vs. group II - 8.98?7.850, p < 0,01). A statistically significant difference was found after 16 weeks in functional motor outcome as well, on behalf of the group I: functional motor abilities level in the group I was 1.86 vs. 2.71 in the group II, p < 0.05. Conclusion. Botulinum toxin type A application leads to an important spasticity decreasing, active range of motion increasing, as well as to functional abilities in children with CP. .

scholarly journals Botulinum Toxin Type A in the Prophylactic Treatment of Chronic Tension-Type Headache: A Multicentre, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study

Cephalalgia ◽  
2006 ◽  
Vol 26 (7) ◽  
pp. 790-800 ◽  
Author(s):  
SD Silberstein ◽  
H Göbel ◽  
R Jensen ◽  
AH Elkind ◽  
R DeGryse ◽  
...  
Keyword(s):  
Botulinum Toxin ◽  
Primary Endpoint ◽  
Botulinum Toxin Type A ◽  
Tension Headache ◽  
Type A ◽  
Botulinum Toxin Type ◽  
Tension Type Headache ◽  
Chronic Tension Type Headache ◽  
Significant Difference ◽  
Type Headache

We studied the safety and efficacy of 0 U, 50 U, 100 U, 150 U (five sites), 86 Usub and 100 Usub (three sites) botulinum toxin type A (BoNTA; BOTOX®; Allergan, Inc., Irvine, CA, USA) for the prophylaxis of chronic tension-type headache (CTTH). Three hundred patients (62.3± female; mean age 42.6 years) enrolled. For the primary endpoint, the mean change from baseline in the number of TTH-free days per month, there was no statistically significant difference between placebo and four BoNTA groups, but a significant difference favouring placebo vs. BoNTA 150 was observed (4.5 vs. 2.8 tension headache-free days/month; P = 0.007). All treatment groups improved at day 60. Although efficacy was not demonstrated for the primary endpoint, at day 90, more patients in three BoNTA groups had ≥50± decrease in tension headache days than did placebo ( P ≤ 0.024). Most treatment-related adverse events were mild or moderate, and transient. BoNTA was safe and well-tolerated in the study.

scholarly journals Use of hyaluronic acid filler and botulinum toxin type A in facial renjuvenation

2010 ◽  
Vol 10 (S1) ◽  
Author(s):  
T Vitagliano ◽  
U Bottoni ◽  
A Greto Ciriaco ◽  
D Novembre ◽  
M Greco
Keyword(s):  
Hyaluronic Acid ◽  
Botulinum Toxin ◽  
Botulinum Toxin Type A ◽  
Type A ◽  
Botulinum Toxin Type
Sign in / Sign up

Export Citation Format

Share Document